CA_(50)、CA_(242)诊断消化系统恶性肿瘤的临床价值

The Clinical Value of Tumor Marker CAso and CA_(242) in Digestive Tract Cancer

目的 糖链抗原CA_(242)和CA_(50)为近年发现的肿瘤血清学标记物,本工作为探讨CA_(50)、CA_(242)在消化道肿瘤中的诊断意义。方法 应用放免法测定164例消化系统恶性肿瘤患者和69例良性疾病患者血清中CA_(50)、CA_(242)水平。结果 两种肿瘤标记物很少在良性疾病患者中升高,假阳性CA_(50) 7.3%,CA_(242) 24.3%。结论 CA_(50)和CA_(242)在消化系统恶性肿瘤患者中的总敏感性分别为70%和63%,CA_(242)在胰管癌的阳性率均较高(79%),两者在肝癌中的敏感性均较低,但在晚期癌瘤患者阳性率较高。

Objective CA_(50) and CA_(242) are newly recognized serum tumor marker. This study is to show their value in the diagnosis of digestive tract tumor Methods 164 patients with malignant digestive disease and 69 patients with benign disease were chosen. CA_(50) and CA_(242) level of these patients were measured by immunoradiometric assay. Results The totalsensitivity of CA_(50) and CA_(242) are 70% and 63% respectively. Two tumor markers rarely elevated in the patients with benign diseases (false positive rate CA_(50) 7.3%, CA_(242) 4.3%). High percentage of elevated CA_(242) level was recorded in the patients with pancreatic and biliary cancers (Sensitivity 79%). Both have low sensitivity in patients with liver carcinoma. Conclusions CA_(50) and CA_(242) are valuable marker in the diagnosis of digestive tract tumor.